New Cabenuva approval in USA

30 March 2022
viiv-big

Cabenuva (cabotegravir/rilpivirine) has been approved in the USA to treat HIV-1 in virologically suppressed adolescents who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either active ingredient.

The regimen was co-developed as part of a collaboration involving the GlaxoSmithKline (LSE: GSK) subsidiary ViiV Healthcare and the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ).

"We are bringing this younger population a first-of-its-kind HIV treatment that is dosed as few as six times a year"This approval marks the first time a long-acting HIV treatment is available for the adolescent population.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical